Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,369 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder OR higher carbohydrate Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Project CARE: CAncer Risk Evaluation

NCT07130487
View directory record Official record
Conditions
Primary Care
Interventions
Relational Agent ( RA) Alex
Behavioral
Lead sponsor
Anita Y. Kinney, PhD, RN
Other
Eligibility
18 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 16, 2026, 10:06 PM EDT
Suspended Phase 1Phase 2 Interventional

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

NCT03704714
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable, Intravascular Large B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available

Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)

NCT00990106
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Combat Disorders, Sleep Disorders
Interventions
prazosin hydrochloride, placebo
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 16, 2026, 10:06 PM EDT
Terminated Phase 1 Interventional

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

NCT00052884
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, amifostine trihydrate, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
16
States / cities
Scottsdale, Arizona • Indianapolis, Indiana • Burnsville, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 16, 2026, 10:06 PM EDT
Terminated Phase 1 Interventional

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

NCT05231668
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
SAR439459, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Placebo, Valganciclovir
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 16, 2026, 10:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Evaluate the Ability of Lactoferrin to Modulate Iron Homeostasis and Exercise Performance in Exercising Females

NCT07546591
View directory record Official record
Conditions
Iron Deficiencies, Low Ferritin, Iron Deficiency, Exercise Performance of Fit Athletes
Interventions
Lactoferrin 100 mg, Lactoferrin 300 mg, Iron Supplementation (5 mg)
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increased Dietary Protein and Meal Frequency Reduces Total and Abdominal Body Fat During Weight Maintenance and Weight Loss

NCT01749449
View directory record Official record
Conditions
Obesity
Interventions
protein and meal frequency
Other
Lead sponsor
Skidmore College
Other
Eligibility
30 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 16, 2026, 10:06 PM EDT
Recruiting Not applicable Interventional

Oral Nutritional Optimization in Total Joint Arthroplasty

NCT04210284
View directory record Official record
Conditions
Osteoarthritis
Interventions
Ensure
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Carbohydrate-protein Co-ingestion on Short-term Recovery

NCT04859491
View directory record Official record
Conditions
Dietary Supplementations
Interventions
Carbohydrate, Carbohydrate-Protein, Placebo
Dietary Supplement
Lead sponsor
Erica Goldstein
Other
Eligibility
35 Years to 59 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 16, 2026, 10:06 PM EDT
Terminated Phase 3 Interventional

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

NCT03926624
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Drug
Lead sponsor
Delta-Fly Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Web-based Weight Loss Intervention

NCT03400696
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Lower carbohydrate diet, Higher fiber diet, Physical activity focused
Behavioral
Lead sponsor
23andMe, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
63,656 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 16, 2026, 10:06 PM EDT
Not listed Phase 2 Interventional

Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea

NCT02069197
View directory record Official record
Conditions
Obesity, Diabetes, Obstructive Sleep Apnea
Interventions
Ketogenic diet, Orlistat, Standardized diet
Other · Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Long-term Effects of Blueberry Supplementation on Brain Health in Older Adults

NCT05764824
View directory record Official record
Conditions
Cognitive Decline, Nutrition, Healthy, Brain Injuries
Interventions
Blueberry powder, Controlled and matched powder
Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years to 99 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics

NCT00150397
View directory record Official record
Conditions
Asthma
Interventions
Tofimilast
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
16
States / cities
Encinitas, California • Riverside, California • DeLand, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 16, 2026, 10:06 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

NCT07222670
View directory record Official record
Conditions
Viral Respiratory Infection, Viral Respiratory Illnesses
Interventions
INNA-051, Placebo
Drug · Other
Lead sponsor
ENA Respiratory Pty Ltd
Industry
Eligibility
18 Years to 45 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • College Park, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Flexibility as a Biomarker of Adaptation to Diet and Exercise Challenges

NCT01987388
View directory record Official record
Conditions
Healthy Volunteers
Interventions
High Intensity Exercise, Low Intensity Exercise, High Carbohydrate Beverage, High Fat Beverage
Other
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
22 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Phase 3 Interventional

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NCT00887536
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
522
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

NCT03926793
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
GB002, Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 16, 2026, 10:06 PM EDT
Recruiting Phase 2 Interventional

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

NCT05554406
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
215
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 10:06 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

NCT04243616
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Cemiplimab, Paclitaxel, Carboplatin (not mandatory), Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Antibiotic "Dysbiosis" in Preterm Infants

NCT02784821
View directory record Official record
Conditions
Enterocolitis, Necrotizing, Bacteremia, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia, Chronic Lung Disease, Ileal Perforation
Interventions
Antibiotic, Gastric fluid, Breast milk, Stool samples, Antibiotics
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
23 Weeks to 33 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 16, 2026, 10:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ascorbic Acid (Vitamin C) Infusion in Human Sepsis

NCT01434121
View directory record Official record
Conditions
Sepsis, Septic Shock, Hypotension, Acute Lung Injury
Interventions
Ascorbic Acid, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 16, 2026, 10:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man

NCT01634646
View directory record Official record
Conditions
Overweight, Elevated Cholesterol
Interventions
Lyzme5
Dietary Supplement
Lead sponsor
Jeff Golini
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Billings, Montana
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 16, 2026, 10:06 PM EDT